UnitedHealth Group vs AstraZeneca: Fair Value & Quality
Both stocks run through our valuation models. Here is how UnitedHealth Group (UNH) and AstraZeneca (AZN) compare, as of Aug 14, 2026.
As of Aug 14, 2026, Fair Value Calculator sees UnitedHealth Group as the more attractively valued of the two: UnitedHealth Group trades at $399 versus a fair value of $526 (+32%), while AstraZeneca trades at $157 versus $127 (-19%).
UnitedHealth Group
UNH · USD · Health Care
+32%
upside to fair value
undervalued
Price$399
Fair Value$526
Quality62/100
AstraZeneca
AZN · USD · Health Care
-19%
upside to fair value
overvalued
Price$157
Fair Value$127
Quality69/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
UnitedHealth GroupAstraZeneca
Valuation
31.9×P/E (TTM)23.6×
0.86×P/S (TTM)4.49×
4.09×P/B5.58×
20.2×EV/EBITDA14.5×
1.49×PEG1.36×
2.1%Dividend yield1.8%
$8.84Dividend per share$3.20
Profitability
3%Net margin17%
8%Operating margin28%
12%Return on equity23%
4%Return on assets8%
Growth
2%Revenue growth (YoY)13%
11.4%Avg. growth/yr (3Y)9.8%
11.7%Avg. growth/yr (5Y)17.2%
Balance & size
0.77×Debt / equity0.51×
$384BMarket cap$271B
healthyGrowth qualityhealthy
AstraZeneca leads: 4 to 10 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
UnitedHealth Groupof which business quality 60 · market factors 79AstraZenecaof which business quality 65 · market factors 49
ProfitabilityMargins and returns on capital today
52
63
Quality GrowthAre margins and returns improving?
48
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
76
60
Low VolatilityCalm price path (market factor)
69
85
MomentumPrice trend over the last 3–12 months (market factor)
81
32
52W MomentumDistance to the 52-week high (market factor)
85
36
Net IssuanceBuybacks instead of dilution
99
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
UnitedHealth Group
DCF Models$362
Earnings-Based$196
Multiples$259
Asset-Based$69.43
Growth DCF$382
Economic Profit$186
Growth Earnings$292
19 of 24 models see the stock below the current price.
AstraZeneca
DCF Models$116
Earnings-Based$60.23
Multiples$125
Asset-Based$21.03
Growth DCF$100
Economic Profit$75.73
Growth Earnings$129
22 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
UnitedHealth Group
Bear $368Fair Value $526Bull $657
$399 = current price (white tick)
AstraZeneca
Bear $72.51Fair Value $127Bull $173
$157 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
UnitedHealth Group · Health Care
Quality score62 · above median
Fair value upside+32% · Top 25%
AstraZeneca · Health Care
Quality score69 · Top 25%
Fair value upside-19% · above median
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees UnitedHealth Group as the more attractively valued of the two: UnitedHealth Group trades at $399 versus a fair value of $526 (+32%), while AstraZeneca trades at $157 versus $127 (-19%).
AstraZeneca has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
